Gryphon International Investment Corp Lowers stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Gryphon International Investment Corp reduced its stake in Gilead Sciences by 2.62% during the most recent quarter end. The investment management company now holds a total of 431,368 shares of Gilead Sciences which is valued at $37,334,900 after selling 11,610 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Jul 21, 2016.Gilead Sciences makes up approximately 8.30% of Gryphon International Investment Corp’s portfolio.

Other Hedge Funds, Including , Rothschild Investment Corp Il boosted its stake in GILD in the latest quarter, The investment management firm added 4,450 additional shares and now holds a total of 29,804 shares of Gilead Sciences which is valued at $2,579,536. Gilead Sciences makes up approx 0.32% of Rothschild Investment Corp Il’s portfolio.Bath Savings Trust Co boosted its stake in GILD in the latest quarter, The investment management firm added 1,390 additional shares and now holds a total of 39,105 shares of Gilead Sciences which is valued at $3,384,538. Gilead Sciences makes up approx 1.04% of Bath Savings Trust Co’s portfolio.Private Bank Trust Co reduced its stake in GILD by selling 830 shares or 15.35% in the most recent quarter. The Hedge Fund company now holds 4,578 shares of GILD which is valued at $397,966. Gilead Sciences makes up approx 0.06% of Private Bank Trust Co’s portfolio.Lgt Capital Partners Ltd. boosted its stake in GILD in the latest quarter, The investment management firm added 31,470 additional shares and now holds a total of 158,180 shares of Gilead Sciences which is valued at $13,563,935. Gilead Sciences makes up approx 2.30% of Lgt Capital Partners Ltd.’s portfolio.

Gilead Sciences closed down -0.55 points or -0.67% at $81.24 with 1,29,94,030 shares getting traded on Thursday. Post opening the session at $81.95, the shares hit an intraday low of $80.62 and an intraday high of $81.98 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016. Gabelli & Co Initiated Gilead Sciences on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $109.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *